Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

Abstract

The IL28B TT genotype is the most important baseline factor for predicting SVR, and a ≥ 4.7 log10 IU/mL reduction in HCV RNA at week 1 is a useful very early on-treatment predictor of SVR, especially in the non-TT genotype.

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

“…Predictors of treatment outcome by telaprevir‐based triple therapy have been reported in real‐world clinical practice in Japan . These reports found that prior treatment response to PEG‐IFN α /ribavirin, IL‐28B genotype and liver fibrosis had an effect on the success of treatment.…”

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

“…In the era of interferon (IFN)‐based therapies for hepatitis C virus (HCV) infection, several factors have been associated with failure to achieve sustained virologic response (SVR), including but not limited to slower viral suppression kinetics, interleukin 28B ( IL28B ) CT or TT polymorphisms, African‐American race, male gender, insulin resistance, older age and, most importantly, advanced fibrosis. While the development of first‐generation protease inhibitors such as boceprevir and telaprevir in combination with pegylated IFN (pegIFN) and ribavirin (RBV) increased SVR rates relative to standalone treatment with pegIFN/RBV, negative predictors of SVR including cirrhosis and prior treatment experience with pegIFN/RBV remained relevant.…”

A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study

“…THIS STUDY IS the first report indicating that T12PR48 regimen results in a significantly higher SVR rate for non‐responders to previous PR than T12PR24 in Japan. Several reports showed that the SVR rate with T12PR24 for previous non‐responders to PR was low, ranging 27–46% . Furthermore, there was a remarkable difference in the SVR rate with T12PR24 between previous partial and null responders in Japan .…”

“…Several reports showed that the SVR rate with T12PR24 for previous non‐responders to PR was low, ranging 27–46% . Furthermore, there was a remarkable difference in the SVR rate with T12PR24 between previous partial and null responders in Japan . The REALIZE study revealed that the SVR rate of partial responders (56.7%) was superior to that of null responders (31.3%) even if null responders were treated with pooled T12PR48 (including T12PR48 and lead‐in T12PR48) .…”

“…In patients with previous relapses, T12PR24 dramatically improved the SVR rate in clinical trials . In Japan, the SVR rate of previous relapsers treated with T12PR24 was very high with more than approximately 90% in clinical practice . On the other hand, in non‐responders including partial and null responders to previous PR, the SVR rate with T12PR24 was only approximately 40% .…”